Abstract
Dopamine agonists (DA) are widely used in the management of prolactinomas, as they are largely effective in controlling tumor secretion and growth. Dopamine agonist administration is safe with only minor adverse effects reported in most cases (e.g., gastrointestinal symptoms and postural hypotension). Neuropsychiatric side effects such as impulse control disorders (ICD; e.g., pathological gambling, compulsive shopping, and hypersexuality) have been described in neurological patients treated for Parkinson’s disease and restless leg syndrome with high doses of DA. Accumulating evidence suggests that ICD in patients with prolactinomas treated with DA are not as rare as previously thought.
We describe a case of microprolactinoma in a perimenopausal female with no known psychiatric history. The patient developed disruptive symptoms of hypersexuality after treatment with cabergoline, which subsequently resolved when cabergoline was discontinued.
Increased awareness regarding possible psychiatric adverse effects with DA administration is needed among endocrinologists, and caution should be exerted in prescribing and monitoring treatment effects.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Vroonen L, Daly AF, Beckers A. Epidemiology and management challenges in prolactinomas. Neuroendocrinology. 2019;109(1):20–7.
Lim CT, Korbonits M. Update on the clinicopathology of pituitary adenomas. Endocr Pract. 2018;24(5):473–88.
Hinojosa-Amaya JM, Johnson N, González-Torres C, Varlamov EV, Yedinak CG, McCartney S, et al. Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas. Front Endocrinol (Lausanne). 2020;11:579606.
Voon V, Fernagut PO, Wickens J, Baunez C, Rodriguez M, Pavon N, et al. Chronic dopaminergic stimulation in Parkinson's disease: from dyskinesias to impulse control disorders. Lancet Neurol. 2009;8(12):1140–9.
Voon V, Napier TC, Frank MJ, Sgambato-Faure V, Grace AA, Rodriguez-Oroz M, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson's disease: an update. Lancet Neurol. 2017;16(3):238–50.
Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–95.
Greenman Y. Prolactinomas and menopause: any changes in management? Pituitary. 2020;23(1):58–64.
American Psychiatric Association. Diagnostic and statistical manual of mental health disorders-V (DSM-V). Washington, DC: American Psychiatric Association; 2013.
Dell’Osso B, Altamura AC, Allen A, Marazziti D, Hollander E. Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci. 2006;256(8):464–75.
Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, Leboucher J, Rousselet M, Thiabaud E, et al. Dopamine agonists and impulse control disorders: a complex association. Drug Saf. 2018;41(1):19–75.
Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, et al. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018;91(3):e189–201.
Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol. 2014;80(6):863–8.
Barake M, Evins AE, Stoeckel L, Pachas GN, Nachtigall LB, Miller KK, et al. Investigation of impulsivity in patients on dopamine agonist therapy for hyperprolactinemia: a pilot study. Pituitary. 2014;17(2):150–6.
Celik E, Ozkaya HM, Poyraz BC, Saglam T, Kadioglu P. Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up. Endocrine. 2018;62(3):692–700.
Martinkova J, Trejbalova L, Sasikova M, Benetin J, Valkovic P. Impulse control disorders associated with dopaminergic medication in patients with pituitary adenomas. Clin Neuropharmacol. 2011;34(5):179–81.
Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z, et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma: a cross-sectional multicenter study. J Clin Endocrinol Metab. 2019;104(7):2527–34.
Viana MC, Andrade LH. Lifetime prevalence, age and gender distribution and age-of-onset of psychiatric disorders in the Sao Paulo metropolitan area, Brazil: results from the Sao Paulo megacity mental health survey. Braz J Psychiatry. 2012;34(3):249–60.
Ozkaya HM, Sahin S, Korkmaz OP, Durcan E, Sahin HR, Poyraz BC, et al. The prevalence of impulse control disorders in patients with acromegaly and prolactinomas treated with dopamine agonists. J Endocr Soci. 2020;4:MON-293.
Grall-Bronnec M, Sauvaget A, Perrouin F, Leboucher J, Etcheverrigaray F, Challet-Bouju G, et al. Pathological gambling associated with aripiprazole or dopamine replacement therapy: do patients share the same features? Rev J Clin Psychopharmacol. 2016;36(1):63–70.
Vriend C. The neurobiology of impulse control disorders in Parkinson's disease: from neurotransmitters to neural networks. Cell Tissue Res. 2018;373(1):327–36.
Weintraub D, Nirenberg MJ. Impulse control and related disorders in Parkinson's disease. Neurodegener Dis. 2013;11(2):63–71.
Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. Eur J Endocrinol. 2019;180(1):31–40.
Ahlskog JE. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease. Physiol Behav. 2011;104(1):168–72.
Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724–63.
Seeman P. Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse. 2015;69(4):183–9.
MacDonald HJ, Stinear CM, Ren A, Coxon JP, Kao J, Macdonald L, et al. Dopamine gene profiling to predict impulse control and effects of dopamine agonist ropinirole. J Cogn Neurosci. 2016;28(7):909–19.
De Sousa SM, Chapman IM, Falhammar H, Torpy DJ. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine. 2017;55(2):618–24.
Bakker IC, Schubart CD, Zelissen PM. Successful treatment of a prolactinoma with the antipsychotic drug aripiprazole. Endocrinol Diabetes Metab Case Rep. 2016;2016:160028.
Burback L. Management of a microprolactinoma with aripiprazole in a woman with cabergoline-induced mania. Endocrinol Diabetes Metab Case Rep. 2015;2015:150100.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Capatina, C., Poiana, C., Fleseriu, M. (2022). Dopamine Agonist-Induced Impulse Control Disorders. In: Davies, T.F. (eds) A Case-Based Guide to Clinical Endocrinology. Springer, Cham. https://doi.org/10.1007/978-3-030-84367-0_4
Download citation
DOI: https://doi.org/10.1007/978-3-030-84367-0_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-84366-3
Online ISBN: 978-3-030-84367-0
eBook Packages: MedicineMedicine (R0)